Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Rajnish Wellness Ltd

RAJNISH
BSE
0.50
3.85%
Last Updated:
30 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Rajnish Wellness Ltd

RAJNISH
BSE
0.50
3.85%
30 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
51Cr
Close
Close Price
0.50
Industry
Industry
Pharmaceuticals Bulk Drugs & Formulation
PE
Price To Earnings
PS
Price To Sales
1.11
Revenue
Revenue
46Cr
Rev Gr TTM
Revenue Growth TTM
-34.68%
PAT Gr TTM
PAT Growth TTM
-236.25%
Peer Comparison
How does RAJNISH stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
RAJNISH
VS

Quarterly Results

Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
6919222716179651223
Growth YoY
Revenue Growth YoY%
87.285.8174.6174.7372.591.5-5.9-58.1-78.6-72.0-31.1156.5
Expenses
ExpensesCr
7818212616179641225
Operating Profit
Operating ProfitCr
-10001000-100-1
OPM
OPM%
-25.20.30.21.32.00.02.81.4-10.64.0-1.9-5.9
Other Income
Other IncomeCr
110000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
-11000000000-1
Tax
TaxCr
000000000000
PAT
PATCr
-11000000000-1
Growth YoY
PAT Growth YoY%
40.2-19.1-37.5-73.7124.1-69.1180.0-30.0-264.329.4-78.6-1,400.0
NPM
NPM%
-20.36.50.50.51.01.01.60.8-8.04.80.5-3.9
EPS
EPS
0.00.00.00.00.00.00.00.00.00.00.00.0

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
1325284214132626774946
Growth
Revenue Growth%
92.28.751.5-67.0-3.098.2-2.3196.9-36.7-6.2
Expenses
ExpensesCr
1324243514172727754948
Operating Profit
Operating ProfitCr
01370-30-120-2
OPM
OPM%
3.64.712.015.61.0-23.7-0.7-4.32.60.0-4.5
Other Income
Other IncomeCr
00100412011
Interest Expense
Interest ExpenseCr
00111000100
Depreciation
DepreciationCr
00000000000
PBT
PBTCr
0146-100110-1
Tax
TaxCr
00120000000
PAT
PATCr
0124-100010-1
Growth
PAT Growth%
97.5281.174.0-114.4116.4293.217.4124.6-83.3-730.1
NPM
NPM%
2.52.58.810.2-4.40.81.51.81.40.4-2.4
EPS
EPS
64.7127.755.70.10.00.00.00.00.00.00.0

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
00355511777777102
Reserves
ReservesCr
013181717126778
Current Liabilities
Current LiabilitiesCr
56109644617410
Non Current Liabilities
Non Current LiabilitiesCr
012169910632
Total Liabilities
Total LiabilitiesCr
5818323335359910691121
Current Assets
Current AssetsCr
58173132333438817584
Non Current Assets
Non Current AssetsCr
000011161251637
Total Assets
Total AssetsCr
5818323335359910691121

Cash Flow

Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
-2-3-9-700-622-4
Investing Cash Flow
Investing Cash FlowCr
000000009
Financing Cash Flow
Financing Cash FlowCr
131050162-2-5
Net Cash Flow
Net Cash FlowCr
001-101-100
Free Cash Flow
Free Cash FlowCr
-2-3-9-700-622-4
CFO To PAT
CFO To PAT%
-261.8-132.7-212.11,069.788.4-3.0-13,493.4164.9-2,454.4
CFO To EBITDA
CFO To EBITDA%
-142.2-97.9-137.8-4,846.4-2.86.65,592.186.0-60,658.6

Ratios

Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
0007095881,27649971
Price To Earnings
Price To Earnings
0.00.00.016.40.053.6226.61,660.0649.00.0
Price To Sales
Price To Sales
0.00.00.01.70.60.43.349.46.51.5
Price To Book
Price To Book
0.00.00.03.10.40.24.015.46.00.8
EV To EBITDA
EV To EBITDA
0.42.21.111.2121.7-1.6-485.6-1,157.9254.110,068.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
82.466.662.466.842.4-13.29.310.57.45.8
OPM
OPM%
3.64.712.015.61.0-23.7-0.7-4.32.60.0
NPM
NPM%
2.52.58.810.2-4.40.81.51.81.40.4
ROCE
ROCE%
42.231.144.825.10.91.93.40.72.20.6
ROE
ROE%
86.663.140.419.0-2.80.51.80.61.20.2
ROA
ROA%
6.17.613.813.4-1.80.31.10.51.00.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Rajnish Wellness Limited (RWL), incorporated in 2015 and headquartered in Mumbai, is a BSE-listed company focused on the manufacturing, branding, and distribution of **Ayurvedic, pharmaceutical, nutraceutical, and personal care products**. The company operates primarily in the **sexual wellness, energy revitalization, and healthcare segments**, with a growing footprint in the **pharmaceutical retail and lifestyle wellness space**. RWL combines an **asset-light business model** with **indigenous R&D** and a **pan-India distribution network**, positioning itself as an innovative and scalable player in India’s evolving wellness and healthcare ecosystem. --- ### **Core Business Segments** RWL operates through two primary business verticals: 1. **PlayWin – Sexual & Lifestyle Wellness** - Flagship brand launched in 2015, contributing the **majority of company revenues**. - Focuses on addressing **low libido, stress-induced sexual dysfunction, and personal wellness** for both men and women. - Offers a complete range of **Ayurvedic sexual wellness products**, including: - *PlayWin Capsules* (male/female enhancement) - *PlayWin Oil & Lotion* (personal lubricants and skin care) - *PlayWin Condoms* - *Kasaav Powder* (female sexual supplement) - *Rajnish Malam* - Products are **FDA-approved**, safe for diabetics and hypertensive patients, and available **over-the-counter** and through medical stores. - Strong brand recognition in **Maharashtra and North India**, with ongoing expansion into Tier II/III cities and southern states. 2. **Dava Discount – Pharmacy & Healthcare Retail** - A **franchise-based pharmacy retail chain** launched in 2021, offering **branded medicines at flat discounts (20–25%)** with home delivery. - Positioned to capitalize on rising demand for **affordable healthcare and online medicine purchases**. - As of 2025, the network has grown to **over 100 franchise outlets** across India, with ambitious plans to expand further. - Offers **allopathic, Ayurvedic, and naturopathic products**, creating a **comprehensive wellness platform**. --- ### **Business Model & Operations** - **Asset-Light Strategy**: - No in-house manufacturing; outsources production to **GMP-compliant third-party manufacturers** across India. - Maintains full ownership of **brands, formulations, and intellectual property**. - Ensures **quality control, regulatory compliance, and on-time delivery** through dedicated supplier partnerships. - **R&D & Clinical Innovation**: - In-house **clinical pharmacology unit** conducts studies on complex formulations. - Uses **indigenously developed technologies** for product development, reducing dependency on imported processes and lowering R&D costs. - Focus on **safe, effective, and regulatory-compliant formulations**, especially for sensitive categories like sexual wellness. - **Distribution & Sales Channels**: - **Pan-India presence** across **21+ states**. - Network includes: - **500+ super stockists** - **10,000+ distributors** - **100,000+ pharmacy outlets** - Strong **e-commerce presence** via: - Snapdeal, IndiaMART, Clickoncare, Lovenaturalremedies, AyurvedMart, Fineyog - Products available even in **small towns and rural areas**, reflecting deep market penetration. --- ### **Key Strategic Developments (2022–2025)** #### **Expansion of Dava Discount Franchise** - Launched in **2021**, Dava Discount has scaled rapidly, with: - **Flat 25% discount model** (2023–2024) refined to **20%** in company-owned stores (e.g., Malad East, Goregaon). - Strategic **company-owned outlets** opened in **Mumbai (Goregaon, Malad), Guwahati, Hubli, Howrah**, and other Tier II cities. - Plans to open **20 new outlets (2024)**, expected to generate **₹300–400 million in annual revenue** with **5–9% operating margins**. - Franchisees receive **marketing support, territorial exclusivity, and competitive supply pricing**. #### **Innovative Retail Formats** - **Medical cum Supermarket** opened in **Malad East, Mumbai (Oct 2023)**: - Combines **pharmacy services with grocery and daily essentials**, offering **10–80% discounts on non-pharma items**. - Includes professional **health consultations, ample parking, and home delivery**. - Aims to create **integrated healthcare-retail hubs** in urban centers. #### **Strategic Partnership with SSSG (Aug 2022)** - Collaboration with **Shree Swami Samarth Gurupeeth (SSSG)**, a large Ayurvedic organization with: - **1,000+ outlets** across India - **1 million+ daily customers** - Upcoming **1,000-bed multispecialty hospital** - Partnership benefits: - RWL gains **access to SSSG’s vast distribution network**. - Dava Discount will **supply medicines** to SSSG’s pharmacy and hospital. - SSSG’s **Ayurvedic and cosmetic products** added to Dava Discount’s portfolio. - Enhances **omnichannel reach** and strengthens **brand credibility**. #### **Growth Ambition** - Goal to open **1,000 Dava Discount stores by 2025** to increase access to **affordable, quality medicines**. - Expansion targets include **Maharashtra, Gujarat, Tamil Nadu, Andhra Pradesh, and Delhi**. --- ### **Marketing & Branding Strategy** - **360-degree approach** for PlayWin: - Utilizes **print, digital, social media, hoardings, public transport, and reality show sponsorships**. - Conducts **sexual wellness awareness programs** in schools, NGOs, and communities to **destigmatize the category**. - Led by promoter **Mr. Rajnishkumar S. Singh**, with a focus on **Tier I, II, and III cities**. - In-house **multi-lingual customer care** team supports consumer engagement and loyalty. --- ### **Corporate & Financial Highlights** - **Market Position**: Leading Ayurvedic sexual wellness brand with **first-mover advantage** in a niche, high-growth category. - **Revenue Drivers**: PlayWin (core), Dava Discount (high-growth retail arm). - **Recent Offer Rejection (Nov 2024)**: - Declined acquisition offer from **Python Chemical Company Limited**, citing **undervaluation**. - Management confident in **independent growth trajectory**, supported by **sector tailwinds** and **strong brand equity**.